Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27538482 | 0.81 | TSHR (0.39) | TSHRCHRNB2CHRNA4HTR2ATAAR1 | |
| SCHEMBL8704773 | 0.81 | SLC6A4 (0.39) | TSHRCHRNB2CHRNA4HTR2ATAAR1 | |
| SCHEMBL14584327 | 0.81 | SLC6A4 (0.39) | TSHRCHRNB2CHRNA4HTR2ATAAR1 | |
| SCHEMBL3687824 | 0.80 | TSHR (0.38) | TSHRCHRNB2CHRNA4GSRSLC6A4 | |
| SCHEMBL16872478 | 0.78 | HRH1 (0.38) | TSHRCHRNB2CHRNA4HTR2ASLC6A4 | |
| SCHEMBL8465860 | 0.76 | HTR2A (0.38) | HTR2ASLC6A4 | |
| SCHEMBL29074535 | 0.76 | ESR1 (0.41) | TSHRTAAR1MTORRAB9A | |
| SCHEMBL29287055 | 0.76 | TSHR (0.38) | TSHRCHRNB2CHRNA4HTR2ATAAR1 | |
| SCHEMBL27556720 | 0.76 | GSR (0.41) | GSRRAB9A | |
| SCHEMBL9174451 | 0.75 | HTR2A (0.39) | TSHRCHRNB2CHRNA4HTR2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528820-B | Apricoxiyet Synthesis method of tam | 浙江国邦药业有限公司 | 2025-10-10 | — | — | CN | disclosed |
| CN-111801339-B | 5-Fluorouracil compounds | 纽科利制药公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-119528820-A | Apricoxiyet Synthesis method of tam | 浙江国邦药业有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119528820-A | Apricoxiyet Synthesis method of tam | 浙江国邦药业有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-111801339-A | 5-fluorouracil compounds | 纽科利制药公司 | 2020-10-20 | — | — | CN | disclosed |
| WO-2019149091-A1 | PROBUCOL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 北京德默高科医药技术有限公司 | 2019-08-08 | — | — | WO | disclosed |
| EP-2430029-B1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2018-01-10 | — | — | EP | disclosed |
| US-9499563-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-11-22 | — | — | US | disclosed |
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2014-10-02 | — | — | US | disclosed |
| US-8785638-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-07-22 | — | — | US | disclosed |
| US-4439230-A | PLANT SAFENING AGENTS | CIBA-GEIGY CORPORATION (US) | 1984-03-27 | — | — | US | disclosed |
| US-4437879-A | Oxime derivatives for protecting plant crops | CIBA-GEIGY CORPORATION (US) | 1984-03-20 | — | — | US | disclosed |
| US-4388106-A | ANTIDOTES AGAINST HERBICIDES | CIBA-GEIGY CORPORATION (US) | 1983-06-14 | — | — | US | disclosed |
| US-4353735-A | ANTIDOTES TO HARMFUL EFFECTS OF HERBICIDES | CIBA-GEIGY CORPORATION (US) | 1982-10-12 | — | — | US | disclosed |
| US-4339454-A | ANTICONVULSANTS | COLGATE-PALMOLIVE COMPANY (US) | 1982-07-13 | — | — | US | disclosed |
| US-4249005-A | NON-HYPNOTIC ANTICONVULSIVE | BRISTOL-MYERS COMPANY (US) | 1981-02-03 | — | — | US | disclosed |
| US-4125552-A | FROM A HALIDE, AMMONIA, HYDROCARBYLAMINE, HYDROGEN SULFIDE AND SULFUR | DOW CORNING CORPORATION (US) | 1978-11-14 | — | — | US | disclosed |
| US-4082790-A | ORGANIC HALIDE, HYDROGEN SULFIDE, AMMONIA OR AMINE, POLAR SOLVENT | DOW CORNING CORPORATION (US) | 1978-04-04 | — | — | US | disclosed |
| US-4046894-A | Certain barbituric acid derivatives used as anticonvulsant agents | BRISTOL-MYERS COMPANY (US) | 1977-09-06 | — | — | US | disclosed |
| US-3931297-A | 10-Hydroxy PGC compounds | SYNTEX (U.S.A.) INC. (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | TSHR 4614/4885CHRNB2 4798/4885CHRNA4 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.